Roche as the leading global company in the field of pharmaceuticals and diagnostics has set the development of science for the goal of improving human life as its main task and created the NAVIFY TumorBoard Solution, which makes doctors’ fight against cancer easier.
Cancer is one of the 21st century’s most widely spread diseases globally. To win it and extend human life expectancy, Roche continues the fast expansion in the range of its digital services. The NAVIFY Tumor Board Solution is a virtual system/platform, which enables not only a quality monitoring of treatment data, but also the organization of remote medical councils, enabling also consultations with other experts worldwide to set the necessary treatment course for the patient.
NAVIFY Tumor Board Solution optimizes the amount of work by creating an individual patient card for each treated person, with all the necessary information gathered in one place and being available to other medical specialists. This enables doctors to be acquainted with a wider information and to take the right decisions based on the information acquired.
Yet Roche Diagnostics plans to develop this system in the future by making the system even more digital, including the use of artificial intelligence to support doctors and medical staff to take even better decisions for the successful fight against cancer.
Learn more about NAVIFY Tumor Board Solution on https://www.navify.com .
Roche, having gathered pharmacy and diagnostics “under one roof”, has become the leader in the field of personalized healthcare: its strategy is to find the most appropriate treatment with the best possible results for each patient.
Roche is the world’s leading biotechnological company with truly special medications in oncology, immunology, infectology, ophthalmology, and neuroscience. Roche is also the world’s leader in the laboratory (in vitro) diagnostics and tissue-based cancer diagnostics, as well as plays a significant role in diabetes care.
Roche Group, with its headquarters located in Basel, Switzerland, operated in more than 100 countries and employed more than 94 000 people in 2016. Roche invested EUR 9.22 billion in science and research, and its turnover reached EUR 47.12 billion. US company Genentech is fully owned by Roche Group. Roche is the majority shareholder in Japanese company Chugai Pharmaceutical.